Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;19(11):2835-2840.
doi: 10.1111/jth.15488. Epub 2021 Aug 19.

Generation of a humanized FXII knock-in mouse-A powerful model system to test novel anti-thrombotic agents

Sarah Beck  1   2 , David Stegner  1   2 , Stefan Loroch  3 , Ayesha A Baig  1   2 , Vanessa Göb  1 , Cornelia Schumbrutzki  3 , Eva Eilers  3 , Albert Sickmann  3   4   5 , Frauke May  6 , Marc W Nolte  6 , Con Panousis  7 , Bernhard Nieswandt  1   2
Affiliations
Free article

Generation of a humanized FXII knock-in mouse-A powerful model system to test novel anti-thrombotic agents

Sarah Beck et al. J Thromb Haemost. 2021 Nov.
Free article

Abstract

Background: Effective inhibition of thrombosis without generating bleeding risks is a major challenge in medicine. Accumulating evidence suggests that this can be achieved by inhibition of coagulation factor XII (FXII), as either its knock-out or inhibition in animal models efficiently reduced thrombosis without affecting normal hemostasis. Based on these findings, highly specific inhibitors for human FXII(a) are under development. However, currently, in vivo studies on their efficacy and safety are impeded by the lack of an optimized animal model expressing the specific target, that is, human FXII.

Objective: The primary objective of this study is to develop and functionally characterize a humanized FXII mouse model.

Methods: A humanized FXII mouse model was generated by replacing the murine with the human F12 gene (genetic knock-in) and tested it in in vitro coagulation assays and in in vivo thrombosis models.

Results: These hF12KI mice were indistinguishable from wild-type mice in all tested assays of coagulation and platelet function in vitro and in vivo, except for reduced expression levels of hFXII compared to human plasma. Targeting FXII by the anti-human FXIIa antibody 3F7 increased activated partial thromboplastin time dose-dependently and protected hF12KI mice in an arterial thrombosis model without affecting bleeding times.

Conclusion: These data establish the newly generated hF12KI mouse as a powerful and unique model system for in vivo studies on anti-FXII(a) biologics, supporting the development of efficient and safe human FXII(a) inhibitors.

Keywords: animal models; blood coagulation; factor XII; hemostasis; thrombosis.

PubMed Disclaimer

References

REFERENCES

    1. Nickel KF, Long AT, Fuchs TA, Butler LM, Renne T. Factor XII as a therapeutic target in thromboembolic and inflammatory diseases. Arterioscler Thromb Vasc Biol. 2017;37:13-20.
    1. Renne T, Stavrou EX. Roles of factor XII in innate immunity. Front Immunol. 2019;10:2011.
    1. Didiasova M, Wujak L, Schaefer L, Wygrecka M. Factor XII in coagulation, inflammation and beyond. Cell Signal. 2018;51:257-265.
    1. Girolami A, Ruzzon E, Lombardi AM, Cabrio L, Randi ML. Thrombosis-free surgical procedures in severe (Homozygote) factor XII deficiency: report of four additional cases and literature review. Clin Appl Thromb Hemost. 2004;10:351-355.
    1. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202:271-281.

Publication types